LncRNA BC promotes lung adenocarcinoma progression by modulating IMPAD1 alternative splicing

BACKGROUND: The therapeutic value of targeted therapies in patients with lung cancer is reduced when tumours acquire secondary resistance after an initial period of successful treatment. However, the molecular events behind the resistance to targeted therapies in lung cancer remain largely unknown....

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qi Wen, Cai, Qian Qian, Yang, Ying, Dong, Shu, Liu, Yuan Yuan, Chen, Zhong Yi, Kang, Chun Lan, Qi, Bing, Dong, Yi Wei, Wu, Wei, Zhuang, Li Ping, Shen, Ye Hua, Meng, Zhi Qiang, Wu, Xing Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845120/
https://www.ncbi.nlm.nih.gov/pubmed/36650118
http://dx.doi.org/10.1002/ctm2.1129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845120/
https://www.ncbi.nlm.nih.gov/pubmed/36650118
http://dx.doi.org/10.1002/ctm2.1129

Ejemplares similares